Furthermore, blocking the pathway at the level of WNT/FZD/DVL, in contrast to targeting the β-catenin/TCF complex [75], would not only impact on canonical signaling but also provide a novel interface for interfering with autocrine EGFR activity, an important target in breast cancer [22,32]. This evidence concerns the gene DVL1 and breast carcinoma.